Azienda Sanitaria Territoriale Pesaro e Urbino (AST PU)

At the AST PU site in Fano, clinical trials in neoplasms focus on improving care for people with lung cancer, breast cancer, and other advanced solid tumors. The studies are designed to test new treatment strategies, compare their effectiveness with current options, and support better outcomes in difficult-to-treat cancers.

• Research in non-small cell lung cancer, including ALK-positive, HER2-overexpressing, and EGFR-mutated disease
• Trials in breast cancer, especially triple-negative and endocrine-responsive early breast cancer
• Studies in advanced solid tumors aimed at evaluating new anticancer approaches

This portfolio reflects a strong focus on testing innovative therapies and measuring whether they can improve survival, delay disease progression, or reduce recurrence in oncology.

Clinical research in digestive system diseases at this health care institution includes studies for ulcerative colitis, with the goal of improving symptom control and achieving better disease remission. These trials are exploring new options for people living with chronic inflammatory bowel disease.

• Studies in ulcerative colitis focused on reducing inflammation and inducing clinical remission
• Evaluation of new treatment options for moderately to severely active disease
• Research aimed at improving quality of life for patients with chronic gastrointestinal inflammation

The work in this area is centered on advancing therapies that may offer better disease control for patients who have not responded adequately to standard care.

The site is actively involved in trials for several forms of non-small cell lung cancer, including locally advanced, metastatic, and biomarker-defined disease. These studies are assessing new combinations and targeted treatments to improve progression-free survival, overall survival, and response to therapy.

• ALK-positive non-small cell lung cancer with disease progression after prior targeted treatment
• Locally advanced or metastatic non-squamous non-small cell lung cancer with HER2 or EGFR alterations
• Testing novel treatment combinations for better control of advanced lung cancer

These trials highlight a major interest in precision oncology, with the aim of matching new therapies to specific tumor features and improving outcomes for patients with advanced disease.

Research in breast cancer at AST PU includes studies for both high-risk and early-stage disease. The main purpose is to determine whether new or differently timed treatment approaches can better prevent recurrence and strengthen long-term disease control.

• Triple-negative breast cancer after curative-intent treatment
• Endocrine-responsive early breast cancer in post-menopausal patients
• Evaluation of approaches intended to improve disease-free survival and reduce relapse risk

These trials combine interest in immunotherapy and treatment sequencing, reflecting efforts to refine how breast cancer is managed after primary therapy.

Another important area of research includes advanced cancers, where investigators are evaluating new anticancer combinations for patients with limited treatment options. The studies aim to determine whether these approaches can improve tumor control and extend survival compared with current standards.

• Trials in advanced solid tumors with a focus on treatment response
• Combination strategies for metastatic or unresectable disease
• Assessments of new therapies intended to improve overall survival and progression-free survival

This research broadens the oncology portfolio at the Fano site by exploring innovative options across multiple tumor types.